TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
35 hedge funds and large institutions have $24M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 5 closing their positions.
835% more call options, than puts
Call options by funds: $748K | Put options by funds: $80K
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
5% less capital invested
Capital invested by funds: $25.4M → $24M (-$1.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LA
Linden Advisors
New York
|
+$429K |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$382K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$252K |
| 4 |
Bank of New York Mellon
New York
|
+$144K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$70.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$457K |
| 2 |
Two Sigma Advisers
New York
|
-$309K |
| 3 |
Two Sigma Investments
New York
|
-$296K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$251K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$55K |
TCON Hedge Fund Activity: Q1 2022 in Review
35 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2022, worth a combined $24M — down 5.3% from $25.4M a quarter earlier.
Fund positioning in TCON was balanced in Q1 2022: 5 funds opened new positions, 5 closed out, 10 added to existing stakes and 7 trimmed.
The largest buyer was Linden Advisors, adding an estimated $429K. The largest seller was Renaissance Technologies, cutting an estimated $457K.
- 35 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $24M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 5.3% quarter-over-quarter.
- 5 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of 0 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Linden Advisors, an estimated $429K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Renaissance Technologies, an estimated $457K sold.
Based on aggregated 13F filings for Q1 2022.